In 1969 Themis was founded on a path-breaking partnership with Gedeon Richter Ltd., Hungary. From the start, partnerships are what givs us strength.
Themis has manufacturing and marketing arrangements with leading MNCs for within the country.
How does it work for our Partners
Marketing, distribution and even product incubation are areas that are ripe for collaboration.
Ready availability of a large range of innovative formulations
Our growing basket of differentiated injectables, API and other products re proven in varied markets and have a high acceptance with health-care experts. The benefits of our PPT (Patented Platform Technology) – incisive products that are break-throughs, faster product development cycles and highly detailed documentation of results and trails – are available for our partners. We ensure the that there is focus on core issues of critical therapies, so our partners can focus on market expansion.
Our manufacturing facilities are WHO-GMP Certified. Besides this we have exclusive tie-ups with sites having EUGMP, USFDA, PICS, MHRA approved facilities.
Our four state-of-the-art manufacturing plants are process driven. Our investment in improving technology, enhancing training and bettering manufacturing processes is continuous. The factory technicians are skilled and the adherence to production schedules is clock-work. Our distribution and delivery support is deadline-driven, quality-controlled and absolutely as promised.
In the final analysis, beyond the numbers, what we look for in partners is a shared concern and that is the enhancement of human health.
We want to take the world from pain to pain-free parentals through pain free work on dedicated innovations. Emal – the first in the world injectable against critical malaria, Etojet – the worlds first painless Etrocoxib injection and a first of its kinds injectable.
Diclofenac sodium for pain relief, are all a result of pursuit of ideas taken to their full potential. Our aim is to make disease management easier and painless for both patients and healthcare professionals.
- Intimation of Board Meeting on May 28, 2019 16/May/2019
- Initial Disclosure to be made by an entity identified as a Large Entity 01/May/2019
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2019. 29/Apr/2019
- Intimation under regulation 39(3) 9f Securities and Exchange Board of India (Listing Obligations and Disclosure Reguirements) Regulation, 2015 I“SEBI (LODR) Regulations, 2015″] 02/Apr/2019
- Change in directors of company 27/Mar/2019
11/12, Udyog Nagar,
S. V. Road, Goregaon (W),